Genzyme Norge HomeKontaktGenzyme Corporate Home
OM OSS
BEHANDLINGSOMRÅDER
PRODUKTER
Genzyme

OM OSS
Genzyme i Norden
Genzyme Biosurgery
Karriere og Jobb
Genzyme Forskning og Utvikling
Genzyme Globalt


International Rare Disease Day28-02-2011

CAMBRIDGE, Mass. – Genzyme Corporation (NASDAQ: GENZ) today recognized International Rare Disease Day with the launch of a new program, the Genzyme Patient Advocacy Leadership Awards (PAL Awards). A global grant program, the Genzyme PAL Awards will support non-profit organizations that work on behalf of patients living with lysosomal storage disorders (LSDs), a group of rare, inherited disorders that cause progressive and debilitating health problems. A total of ,000 will be awarded through a competitive application process to organizations that seek funding for new initiatives that support the LSD patient community.

“For 30 years, Genzyme has been supporting patients through pioneering new treatments, free drug programs and through ongoing partnerships with patient organizations that serve the LSD patient community,” said Genzyme’s Director of Patient Advocacy, Jamie Manganello. “International Rare Disease Day is a great moment to launch the PAL Awards to commemorate the progress that has been made in partnership with the patient community, and as a reminder of our commitment to the work that is still ahead for us on behalf of patients and families affected by rare diseases.”

Organizations may apply for a Genzyme PAL Award for programs that support disease awareness, advocacy on behalf of patient communities, patient education and patient care, support and communication networks. This grant program is supplemental to Genzyme’s existing grants program and will not replace the contributions made locally each year to support advocacy groups. Proposals will be reviewed by an external review committee. Applications must be received by June 15, 2011, and the award recipients will be announced by July 31, 2011. For more information on the Genzyme PAL Awards program, or to apply for a grant, please visit www.genzymeadvocacyawards.com.

February 28, 2011 marks the fourth International Rare Disease Day, created by the patient organization EURORDIS and involving rare disease organizations globally. Genzyme is proud to have been a partner each year for International Rare Disease Day, and has organized events at Genzyme locations around this year’s theme, “Rare but Equal.” These events include presentations by patients with rare diseases at Genzyme offices, participation in a public event at the Massachusetts State House and today’s launch of the Genzyme PAL Awards.

About Genzyme
One of the world's leading biotechnology companies, Genzyme is dedicated to making a major positive impact on the lives of people with serious diseases. Since 1981, the company has grown from a small start-up to a diversified enterprise with approximately 10,000 employees in locations spanning the globe.

With many established products and services helping patients in 100 countries, Genzyme is a leader in the effort to develop and apply the most advanced technologies in the life sciences. The company's products and services are focused on rare inherited disorders, kidney disease, orthopaedics, cancer, transplant, and immune disease. Genzyme's commitment to innovation continues today with a substantial development program focused on these fields, as well as cardiovascular disease, neurodegenerative diseases, and other areas of unmet medical need. Genzyme’s press releases and other company information are available at www.genzyme.com and by calling Genzyme’s investor information line at 1-800-905-4369 within the United States or 1-678-999-4572 outside the United States.

Important Information
Genzyme has filed with the Securities and Exchange Commission a Solicitation/Recommendation Statement on Schedule 14D-9 relating to the tender offer by Sanofi-Aventis. Genzyme shareholders are advised to read the company's Solicitation/Recommendation Statement on Schedule 14D-9 because it contains important information. Shareholders may obtain a free copy of the Solicitation/Recommendation Statement on Schedule 14D-9, as well as any other documents filed by Genzyme in connection with the tender offer, free of charge at the SEC's website at www.sec.gov. In addition, investors can obtain free copies of these documents from Genzyme by directing a request to Genzyme at 500 Kendall Street, Cambridge, MA 02142, Attention: Shareholder Relations Department, or by calling 617-252-7500 and asking for the Shareholder Relations Department.

Genzyme Corporate


24-11-2014 - European CHMP Adopts Positive Opinion for Genzyme’s Cerdelga® (eliglustat) Capsules
05-11-2014 - Genzyme Announces Enrollment of First Patient in Phase II Vatelizumab Trial in Relapsing Remitting Multiple Sclerosis
22-08-2014 - FDA Approves Genzyme’s Cerdelga (eliglustat) Capsules - Only First-Line Oral Treatment for Adult Gaucher Disease Type 1
28-05-2014 - Genzyme Recognizes Sixth Annual World MS Day
12-12-2013 - FDA Grants Priority Review for Genzyme’s Cerdelga™ (eliglustat), an Investigational Oral Therapy for Gaucher Disease - - Second Major Regulatory Filing Following EMA Acceptance in Late October -
15-11-2013 - To nye MS-medikamenter lanseres i Norge
19-09-2013 - Europeiske legemiddelmyndigheter/EU-kommisjonen godkjenner Lemtrada™ (alemtuzumab), medikament for behandling av multippel sklerose
03-09-2013 - Europeiske legemiddelmyndigheter/EU kommisjonen godkjenner Aubagio® (teriflunomide), en gang daglig, oral behandling for pasienter med MS
28-06-2013 - Genzyme Receives Positive CHMP Opinion for LEMTRADA™ (alemtuzumab) in Europe
29-05-2013 - Genzyme Celebrates Fifth Annual World MS Day
25-04-2013 - Once-daily AUBAGIO® Delayed Onset of Clinically Definite Multiple Sclerosis (MS) in TOPIC Study
22-03-2013 - Effect of Genzyme’s LEMTRADA Maintained in Patients Beyond Two-Year Pivotal MS Studies
13-03-2013 - Multiple Presentations Highlight Continuing Progress of AUBAGIO and LEMTRADA Programs
27-02-2013 - Genzyme Receives Company Award from European Organisation for Rare Diseases (EURORDIS)
26-02-2013 - Genzyme Recognizes International Rare Disease Day with Global Awareness Programs and Launch of Third Annual Patient Advocacy Leadership (PAL) Awards
21-02-2013 - Genzyme Announces Positive New Data from Two Phase 3 Studies for Oral Eliglustat Tartrate for Gaucher Disease
01-11-2012 - Genzyme Announces Publication of LEMTRADA (alemtuzumab) Pivotal Studies in The Lancet.
09-10-2012 - Genzyme to Present New Data from AUBAGIO® and LEMTRADATM Clinical Development Programs at ECTRIMS
17-09-2012 - FDA Approves Genzyme’s AUBAGIO® (teriflunomide), a Once-Daily, Oral Treatment for Relapsing Multiple Sclerosis
28-02-2011 - International Rare Disease Day
16-02-2011 - Sanofi-aventis to Acquire Genzyme
13-10-2010 - Genzyme’s Alemtuzumab Shows Sustained Reduction in Relapses and Disability in Five-Year Review of MS Patients from Phase 2 Trial


 

  © 2008 Genzyme. All Rights Reserved. Webmaster